Successful stem cell transplantation depends on cell dose, and this is particularly true for placental/cord blood transplantation in which it has been clearly shown that both the success of engraftment as well as the speed of white cell and platelet recovery are dependent on the nucleated cell dose in the graft. Thus, if stem cell numbers could be increased, the speed as well as the likelihood of engraftment might be improved. We studied the effect of two different cytokine combinationskit ligand (KL), interleukin-3 (IL-3), and Flt-3 ligand supplemented with thrombopoietin and IL-11 (combination 1) or granulocyte/macrophage colony-stimulating factor (GM-CSF) and G-CSF (combination 2)-for their ability to affect speed and extent of engraftment using limited numbers (5 ؋ 10 4 ) of murine bone marrow (BM) light-density (LD) cells or their progeny expanded ex vivo in the presence one or the other cytokine combination for 6 days. With combination 1, we found that speed of platelet recovery was enhanced, but at the expense of white blood cell (WBC) recovery and percent donor engraftment. Furthermore, the cytokine combination that best maintained donor engraftment, combination 2, did so at the expense of platelet recovery. In no case was percent donor engraftment improved over 5 ؋ 10 4 unmanipulated LD BM cells. These results are consistent with the interpretation that immediate recovery of blood cells of different lineages and longterm donor engraftment are separate functions that can be influenced by the choice of cytokines used during the ex vivo expansion process.
INTRODUCTION T
HE ABILITY TO INCREASE the number of hematopoietic stem cells ex vivo would be of value with grafts known to contain low stem cell numbers, such as placental/cord blood (PCB). With PCB transplants, the success and speed of white blood cell (WBC) and platelet engraftment depend on the nucleated cell and colonyforming cell (CFC) dose transplanted per kilogram of recipient body weight (1, 2) . Thus, if the number of stem and progenitor cells could be increased, the speed as well as the likelihood of engraftment might be improved.
Numerous strategies for the expansion of murine and human bone marrow (BM), peripheral blood (PB), and PCB stem and progenitor cells have been devised (3) (4) (5) (6) (7) (8) (9) (10) (11) . Consistently, the numbers of CFCs of different classes can be increased in culture with a variety of cytokines in the presence or absence of serum components and/or stro-mal feeder layers (12) (13) (14) (15) . However, the ability of ex vivo-expanded cells to engraft fully the recipient and produce cells of both lymphoid and myeloid lineages can only be tested rigorously in animal models. To date, the evidence for the successful ex vivo expansion of stem cells responsible for multilineage long-term engraftment is inconclusive. Regardless of which of the currently available cytokines is used, ex vivo cell expansion conditions largely facilitate the maturation of stem cells into lineage-restricted progenitor cells (16, 17) as well as changes in homing features associated with loss of longterm repopulating capacity (18) (19) (20) .
However, other studies suggest that ex vivo expansion can accelerate engraftment and provide short-term radioprotection. Muench reported that the transplantation of BM cells harvested 1 day after the administration of 5-fluorouracil and cultured with interleukin-1 (IL-1) and kit-ligand (KL), led to accelerated myeloid recovery (21) , and others have reported similar findings (22) (23) (24) (25) (26) . Other investigators, however, found a detrimental effect of ex vivo expansion on stem cell function or inconclusive results with regard to long-term engraftment (27) (28) (29) (30) (31) . In fact, there may be different stem and progenitor cell populations that affect different stages of post-transplant recovery (32) (33) (34) (35) (36) (37) (38) (39) . Theoretically, the use of different cytokines for ex vivo expansion might differentially influence the phases of engraftment post-transplantation.
To investigate this possibility, we tested two different cytokine combinations (CC) using a recently reported congenic mouse model that employs myeloablation and transplantation of limiting numbers of BM cells subjected to ex vivo expansion (40) . The cytokines used for expansion in the present study consisted of Flt-3 ligand, KL, and IL-3 supplemented with either IL-11 and thrombopoietin (TPO) (CC 1) or granulocyte/macrophage colony-stimulating factor (GM-CSF) and G-CSF (CC 2). In theory, CC 1 and CC 2 would be more likely to promote platelet or granulocyte recovery, respectively. In addition, TPO and IL-11 are thought to act earlier in hematopoiesis and might retain the long-term engraftment capacity of the ex vivo-expanded cells (5, 10, 11, (15) (16) (17) (41) (42) (43) (44) .
MATERIALS AND METHODS

Mice
Female C57 Bl6 (LY-5.2 and LY-5.1:PEP 3B LY-5.1) mice from Jackson Laboratories (Bar Harbor, ME) were used at 10-14 weeks of age. LY-5.1 mice served as donors and LY-5.2 mice as recipients. Single-dose lethal irradiation (9 Gy from a 137 Cesium source at a dose rate of 72 rads/min) was given in all experiments, and transplantation took place within 8 h post-irradiation. For the first 6-8 weeks post-transplant, mice were maintained in a laminar flow environment in sterilized cages with irradiated food and sterile acidified water supplemented with 2 mg/ml neomycin sulfate (Sigma, St. Louis, MO).
BM and light density cell preparation
Femurs and tibias were flushed with Iscove's modified Dulbecco's medium (IMDM; Gibco BRL, Gaithersburg, MD), and the cells were pooled for further use. LD cells were enriched by centrifugation at 600 ϫ g on Nycoprep (Nycomed, Oslo, Norway; density 1.077). The interface cells were harvested, washed, and resuspended in RPMI medium 1640 (Gibco BRL). All nucleated cell counts were performed using a hemocytometer.
Cytokines
The cytokines used were: 100 ng/ml recombinant (r) rat KL, 10 ng/ml r human (h) GM-CSF, 10 ng/ml rh G-CSF (all from Amgen, Thousand Oaks, CA); 100 U/ml r murine IL-3 (PharMingen, San Diego, CA); 100 ng/ml rh Flt-3 ligand and 20 ng/ml rh IL-11 (both from Genetics Institute, Cambridge, MA); 800 U/ml r murine TPO (kindly provided by Dr. Kenneth Kaushansky) in concentrated condition medium.
Ex vivo expansion of bone marrow light density cells
Freshly harvested light density (LD) cells were placed into culture medium containing IMDM, 2% bovine serum albumin (BSA), 10 M ␤-mercaptoethanol, and 200 g/ml bovine transferrin (all from Sigma); 10 g/ml bovine insulin 100 U and 100 g/ml penicillin-streptomycin, respectively, and 2 mM L-glutamine (all from Gibco BRL); and human lipoprotein concentrate 2% (ICN Pharmaceuticals, Costa Mesa, CA) in 24-well plates for 5-7 days at 37°C in air supplemented with 5% CO 2 . Cells were cultured serum free with various combinations of cytokines at concentrations previously shown to support optimum colony growth. Cultures were seeded with 5 ϫ 10 4 LD cells/ml in each well. Samples were withdrawn at different times for cell counts and CFC assays.
Colony-forming cell assays
A standard methylcellulose assay was used for assessment of GM-CFC, megakaryocytic (Meg) CFC and mixed-cell CFC. Aliquots withdrawn from the liquid suspension cultures were plated in duplicate into 1-ml Petri dishes, each of which contained 15% (vol/vol) horse serum (Gemini Bioproducts, Calabasas, CA), BSA 0.9% (wt/vol), 10 M ␤-mercaptoethanol, 100 U and 100 g/mL penicillin-streptomycin, respectively, 2 mM L-glutamine (both from Gibco), and methylcellulose 0.8% (wt/vol) in IMDM. CFC assays were established with the same combination of cytokines used for the initiation of the original suspension culture. After 7 days of incubation (37°C in 5% CO 2 ) colonies were counted using an inverted light microscope.
Transplantation of expanded bone marrow LD cells
LD cells (5 ϫ 10 4 ) were transplanted into groups of 10-13 mice either as unmanipulated cells or their progeny, which had been cultured for 6 days with CC 1 or CC 2. On day 6, cells were harvested, washed, and resuspended in RPMI. The harvest procedures normally performed on cultured cells were also carried out on the fresh LD cells before transplantation.
Percent donor engraftment
Percent donor engraftment was determined by twocolor fluorescence-activated cell sorting (FACS) analysis with antibodies (Ab) against the leukocyte markers CD45.1 and CD45.2. Ten to 100 l of whole blood were collected from the tail vein and mixed with 40 l of citrate phosphate dextrose adenine (CPD-A). Cells were incubated with rat anti-mouse CD16/32 monoclonal antibody (mAb) (PharMingen) to avoid nonspecific Ab binding to Fc␥R and then stained using fluorescein isothiocyanate (FITC)-conjugated mouse anti-mouse CD45.2 and phycoerythrin (PE)-conjugated mouse anti-mouse CD45.1 (PharMingen). Control studies were performed with FITC-or PE-conjugated mouse immunoglobulin G 2a (IgG 2a ) isotype standards (PharMingen). Two milliliters of FACS lysing solution (Becton Dickinson, San Jose, CA) were added to each sample to lyse red blood cells, and the cells were then washed twice with phosphate-buffered saline (PBS; Gibco, Grand Island, NY). The stained cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). Ab-labeled leukocytes were identified according to their forward and side-angle light scatter and gated electronically. For each probe, 1-1.5 ϫ 10 5 events were acquired. Data were processed using CellQuest software (Becton Dickinson).
Speed of platelet and WBC recovery
For 4-6 weeks following transplantation, blood was obtained daily from 2 different animals from each group. In that manner, no animal was bled more than every 10 days. For platelet and WBC counts, the blood was collected in ThromboPlus tubes (Sarstedt, Nuembrecht, Germany) or Turk's solution, respectively. Nucleated cells and platelets were counted in a hemocytometer.
Statistical analysis
Estimation methods for time to platelet and WBC recovery: For this study, the events of interest were the platelet counts of 3 ϫ 10 5 and 5 ϫ 10 5 /l and the WBC of 10 3 /l and time from the nadir until these platelet or WBC counts were reached. Mice that did not reach the level of 3 ϫ 10 5 platelets/l or 10 3 WBC/l during the study period were considered to be censored observations.
Because it is impossible to obtain laboratory data for each mouse daily, there is no direct measurement of the times that 3 ϫ 10 5 or 5 ϫ 10 5 platelets/l or 10 3 WBC/l were reached. To estimate this time, it was necessary to interpolate between the first observation after 3 ϫ 10 5 platelets/l were reached and the immediately preceding observation. If there was no preceding observation after the nadir day, then the nadir day and the nadir level were used. This method for estimating the time until a certain cell count is reached assumes that all mice in a group engraft on the same day. For those mice with no preceding observation after the time of engraftment, this also assumes the platelet or WBC count was at the nadir level on the day the lowest value was obtained. The nadir day was determined for each group by using the observations where the lowest values occurred, and the nadir level was taken as the average of these two values. The only exception was the group receiving unmanipulated BM cells in the first experiment. Here, the lowest values occurred on different days, and the nadir day was chosen as the midpoint between these days (i.e., day 8 and day 10 had the lowest values; therefore, day 9 was chosen as the nadir day).
Statistical methods for time to platelet and WBC recovery: The probability of reaching the target counts on each day was estimated using the Kaplan-Meier method. The log-rank test was used to determine if there were statistically significant differences between treatment groups.
Statistical method for percent donor engraftment: Percent donor engraftment was assessed by a two-sample ttest for each pair of groups.
RESULTS
Speed of platelet and WBC recovery
Three independent experiments were carried out and the results are shown in Figs. 1 and 2 . To show more clearly the differences between the results obtained with the original cell dose of 5 ϫ 10 4 LD cells and their expanded progeny, engraftment kinetics for 10 6 BM cells are not shown.
In the first two experiments, 5 ϫ 10 4 LD cells or their progeny expanded for 6 days with CC 1 were used. In the third experiment, an additional group was transplanted with cells expanded for 6 days with CC 2. In each experiment, one group of mice was transplanted with 10 6 BM cells, which served as the standard for optimal speed and degree of engraftment.
Platelet recovery: As shown in Fig. 1 , platelet nadirs in each group were reached 8-10 days post-transplant. The nadir in the group transplanted with 10 6 BM cells did not fall below 3 ϫ 10 5 /l, indicating very rapid recovery in this group compared to all other groups. For 10 6 BM cells, statistical comparisons with all other groups were obtained at the level of 5 ϫ 10 5 platelets/l, only.
In the first two experiments, the median times to reach a platelet count of 3 ϫ 10 5 after the nadir were 5.1 days and 2.6 days following transplantation with 5 ϫ 10 4 LD cells and 2.9 days and 1.3 days for the progeny of 5 ϫ 10 4 LD cells expanded for 6 days with CC 1. The groups transplanted with the expanded cells recovered significantly more rapidly than the groups transplanted with 5 ϫ 10 4 LD cells (p ϭ 0.0004 and 0.015, respectively). In the same two experiments, 5 ϫ 10 5 platelets/l were reached after 10.8 and 8.6 days following transplantation of LD cells, after 7.0 and 3.8 days following transplantation of the ex vivo-expanded cells, and after 8.2 days and 1.3 days following transplantation of 10 6 BM cells (data not shown). Even though there is evidence that, in both experiments, mice transplanted with fresh LD cells recovered more slowly than the groups transplanted with expanded cells, the differences lost their significance with the exception of the second experiment when comparing the recovery time of mice transplanted with 5 ϫ 10 4 LD cells and 10 6 BM cells. The group transplanted with 10 6 BM cells recovered significantly more rapidly to 5 ϫ 10 5 platelets/l (p ϭ 0.0023; data not shown).
Because two separate experiments showed more rapid platelet engraftment following transplantation of CC 1-expanded cells, a third experiment was performed with an additional group using cells expanded with CC 2 to determine if, perhaps, this combination would promote speed of WBC recovery.
In the third experiment, as in the first two, transplantation with 5 ϫ 10 4 LD cells led to slower platelet recovery than transplantation with CC 1-expanded cells (4.5 days vs. 3.2 days), although the difference was not statistically significant. The times to reach 3 ϫ 10 5 platelets/l were 10.2 days with CC 2-expanded cells compared to 3.2 days with CC 1-expanded cells (p ϭ 0.0079) (Fig. 1) .
The time to reach 5 ϫ 10 5 platelets/l with 10 6 BM cells was 11.2 days and was significantly faster than in all other groups. Time to recovery was 20.6 days for mice receiving 5 ϫ 10 4 LD cells, 15.7 days for mice receiving CC 1-expanded cells, and 21.2 days with CC 2-expanded cells (p Ͻ 0.0001). Even though the time to reach 5 ϫ 10 5 platelets was faster in mice receiving CC 1-expanded cells compared to mice receiving CC 2-expanded or fresh LD cells, the differences were not statistically significant.
WBC recovery: As shown in Fig. 2 , the time to 10 3 WBC/l in all three experiments was significantly faster in mice receiving fresh LD cells compared to mice transplanted with CC 1-expanded cells: 15.9 versus 20.2 days (p ϭ 0.0078), 17.0 versus 21.2 days (p ϭ 0.0006), and 9.1 versus 16.3 days (p ϭ 0.0014), respectively (Fig. 2) . The time to recovery in mice transplanted with 10 6 BM cells was 10.1, 6.2, and 5.7 days in the same experiments. Although this was faster than any other group, the differences were not significant in all cases. The time to reach 10 3 WBC/l in mice receiving CC 2-expanded cells was 13.3 days and was not significantly different from mice that received CC 1-expanded cells (16.3 days) .
Thus, in three experiments, the time to reach 3 ϫ 10 5 platelets/l was accelerated (significantly in two of the three) in mice receiving CC 1-expanded cells compared to mice receiving fresh LD cells. In the third experiment, where an additional expansion with CC 2 was carried out, platelet recovery was slower than in mice receiving CC 1-expanded cells. For WBC recovery, there was a significant delay with CC 1-expanded cells compared to fresh LD cells in all experiments. The speed of WBC recovery in mice transplanted with cells expanded with CC 2 was neither better nor worse than in mice receiving unmanipulated LD cells.
Extent of cell expansion in culture prior to transplantation
As shown in Fig. 3 , the extent of expansion for total cell and progenitor cell numbers for each experiment varied widely and the results are presented individually so that progenitor cell expansion can be directly related to platelet and WBC engraftment kinetics with each transplant. With CC 1, cell expansion was 16-, 35-, and 42-fold for each of the three experiments. GM-CFC expansion was 8-, 25-, and 42-fold, and megakaryocyte (Meg)-CFC expansion was 2-, 2-, and 21-fold, respectively. Mixed-cell CFC were only detected in fresh LD cells; after 6 days of culture, no mixed-cell CFC were detected. With CC 2, cells were expanded 28-fold and GM-CFC 39-fold. Meg CFC increased from undetectable levels to 700/ml after 6 days of culture, while mixed-cell CFC were undetectable at any time. Total cell and CFC expansion results are shown in Fig. 3 in absolute numbers/ml of culture corresponding precisely to the cell or CFC number transplanted after 6 days of culture.
FIG. 3. Increase in total cell numbers (upper left), GM-CFC (upper right)
and Meg-CFC (lower left) in each of the three experiments reported. Despite the fact that there was a marked increase in the numbers of GM-CFC in experiment 3 with both CC 1 and CC 2, time to WBC recovery was still statistically significantly longer than that seen in mice transplanted with the original 5 ϫ 10 4 cells, although the percent donor engraftment was maintained (see text for details).
Percent donor engraftment
In the third experiment, percent donor engraftment was determined at 10 weeks and 5 months post-transplant. Survival was 100% in all experiments. At 10 weeks, donor engraftment was 93.8% (SEM 3.1%; n ϭ 10) in mice transplanted with 10 6 BM cells; 66.8% (SEM 26.2%; n ϭ 10) with 5 ϫ 10 4 LD cells; 12.1% (SEM 14.5%; n ϭ 13) with CC 1-expanded cells; and 71.0% (SEM 22.0%; n ϭ 13) with CC 2-expanded cells. The difference between the group receiving CC 1-expanded cells was highly significant (p value Ͻ 0.01) compared to CC 2-expanded cells and 5 ϫ 10 4 LD cells. The percent donor engraftment in the group receiving 10 6 BM cells was superior to all other groups. Subsequently, there were no significant changes in engraftment levels 5 months post-transplant (Fig. 4) .
DISCUSSION
The number of hematopoietic stem cells is important in the success of any transplant. This is particularly true for PCB transplants in which the likelihood of engraftment and speed of marrow recovery are related to both the nucleated cell and CFC dose per recipient body weight (1, 2) . This fact has resulted in the cautious application of cord blood transplantation for adults. If one could increase the numbers of stem and progenitor cells prior to transplantation, the clinical outcomes might be improved for this increasingly important stem cell source (45) (46) (47) . However, the results to date of stem cell expansion studies are mixed, and there is little or no convincing evidence that stem cell numbers have been increased significantly as a result of the ex vivo-expansion strategies that have been tested. Furthermore, many of the methods assessing stem cell expansion employ surrogate markers, such as competitive repopulation assays and transplantation of progenitor cells into immunocompromised hosts.
Recently, we reported a murine model testing the repopulating ability of BM cells following ex vivo expansion (40) . The model employs transplantation of limited numbers of BM cells with survival and long-term engraftment compared between mice receiving ex vivo-expanded cells or unmanipulated cells. We found, as have others (31) (32) (33) (34) (35) (36) (37) (38) (39) , that ex vivo expansion with several cytokine combinations failed to improve survival or engraftment. Although the model we used reflects the radioprotective capacity of the transplanted cells, it did not assess the potential of donor cells that were not radioprotective to contribute to engraftment kinetics. This might be relevant because there is evidence that different stem cell populations are responsible for hematopoietic function at different times post-transplantation (32, (48) (49) (50) . Harrison et al., using a competitive repopulation model, showed close correlations between donor type B cells, T cells, platelets, and granulocytes during the first few weeks following transplantation, suggesting that many lymphoid and myeloid cells were descended from common precursors. After 4-6 weeks, the correlations lessened and the level of donor engraftment increased, as estimated by the binomial model in which variability of the data among the recipients is inversely related to the number of donor precursor cells in the graft. The results were interpreted to mean that few or none of the early multilineage precursors possessed long-term engraftment capability (49). Zhong et al. showed several patterns of reconstitution after BM transplantation in a competitive repopulation assay. At low donor cell doses, recipients showing early engraftment became negative 6 weeks post-transplant, suggesting early reconstitution with cells only having short-lived capacity. However, in some, engraftment levels gradually increased, indicating expansion of long-term repopulating cells. Recipients of higher cell doses showed increasingly stable multilineage donor engraftment over the next 6 months (50).
To evaluate the effect of ex vivo expansion on speed of recovery or contribution to long-term engraftment, we used 5 ϫ 10 4 LD cells as the reference cell number. This cell dose guaranteed 100% survival in lethally irradiated mice but was still limiting as reflected by inferior percent donor engraftment compared to animals transplanted with 10 6 BM cells (see Fig. 4 ). We reasoned that if speed of engraftment and long-term marrow reconstitution were dissociable, these functions might be influenced independently by the ex vivo culture conditions used.
For expansion, we used two cytokine combinations consisting of Flt-3 L, KL, and IL-3 supplemented with TPO and IL-11 (CC 1) or GM-CSF and G-CSF (CC 2). TPO and IL-11 would primarily affect megakaryopoiesis, whereas GM-CSF and G-CSF would promote myeloid expansion and differentiation. In three experiments, we transplanted 5 ϫ 10 4 LD cells or their progeny expanded with CC 1 as well as 10 6 unseparated BM cells. In the third experiment, expansion with CC 2 was added. Differences in the time to reach 3 ϫ 10 5 , 5 ϫ 10 5 platelets/l and 10 3 WBC were evaluated. A platelet count of 3 ϫ 10 5 was chosen arbitrarily because it is high enough to determine the initial speed of engraftment (assuming a nadir of Ϸ1.5 ϫ 10 5 /l).
In all three experiments, the time to 3 ϫ 10 5 platelets/l was more rapid in mice transplanted with CC 1-expanded cells compared to 5 ϫ 10 5 LD cells, with statistical significance in the first two experiments. In the third experiment, where expansion with CC 2 was included, there was no statistical difference in platelet recovery between mice transplanted with 5 ϫ 10 4 LD cells and those transplanted with CC 1-expanded cells, but the platelet count in mice transplanted with CC 2-expanded cells recovered more slowly. Differences in recovery rates to 5 ϫ 10 5 platelets/l disappeared between the groups, indicating that the speed of recovery within the first 2 weeks post-nadir was most affected by the ex vivo expansion process.
In contrast to platelet recovery, the time to reach 10 3 WBC/l following expansion with CC 1 was, in all experiments, significantly slower than when fresh LD cells were transplanted. Even expansion with CC 2 failed to hasten WBC recovery and no difference with fresh LD cells was seen. The transplantation of 10 6 BM cells resulted in either the fastest or at least equal platelet and WBC recovery times compared to all other groups.
Surprisingly, cell expansion with CC 1 significantly compromised short-term as well as long-term engraftment. Percent donor engraftment at 10 weeks in mice transplanted with CC 1-expanded cells was only 12.1% as compared to 71.0% or 66.8% when mice were transplanted with CC 2-expanded cells or 5 ϫ 10 4 LD cells. This suggests that TPO and/or IL-11 speeded early platelet recovery but failed to even maintain cells contributing to long-term engraftment. The use of CC 2, in which TPO and IL-11 were replaced by GM-CSF and G-CSF, did not hasten WBC or platelet recovery, but resulted in significantly improved long-term engraftment compared to CC 1. Neither CC achieved the degree of long-term engraftment seen with 10 6 BM cells. This is consistent with our earlier findings in which mice transplanted with limiting numbers of BM cells or their cytokine-expanded progeny showed significantly poorer survival and engraftment outcomes (40) .
The current results suggest that the contribution of expanded cells to early recovery and long-term engraftment can be differentially affected by the cytokines used for expansion. Considering stem cell expansion strategies being tested in the clinic, it would be important to know if the speed of WBC or platelet recovery could be increased, but if it came at the expense of durable long-term engraftment.
Would strategies to shorten the time to marrow recovery be clinically useful? The use of PCB as a source of stem cells for transplantation has become increasingly important, but a major limitation has been the delayed engraftment seen. With adult BM or cytokine-mobilized PB stem cell transplantation, it is widely recognized that the time to neutrophil engraftment correlates with CD34 ϩ cell dose. In addition, other studies found a correlation between the number of Meg CFC administered and time to platelet engraftment following PB transplants (51, 52) . Consequently, many investigators have explored strate-gies to increase the numbers of stem and progenitor cells to shorten WBC and platelet recovery times. There is substantial information available on the clinical use of ex vivo-expanded mobilized PB cells. Brugger et al. were the first to report the transplantation of ex vivo-expanded cells alone for autografting in patients following highdose chemotherapy (53) . A fixed number (11 ϫ 10 6 ) of mobilized CD34 ϩ PB cells were expanded with KL, IL-1, IL-3, IL-6, and erythropoietin in large-scale liquid culture. Infusion of these cells rapidly restored hematopoiesis, and short-term engraftment was comparable, but not superior, to historical controls. The contribution of the ex vivo-expanded cells to long-term engraftment was impossible to determine, however, given that no cell marking system was used.
Ex (56) . Several other groups administered ex vivo-expanded CD34 ϩ cells following high-dose chemotherapy for solid tumors. These studies showed no accelerated hematopoietic recovery but demonstrated the feasibility of expansion procedures and the clinical safety of the approach (57, 58) . Similarly, the feasibility of expansion and transplantation of PCB aliquots together with the unmanipulated graft was recently shown (59, 60) . To date, it seems that neutrophil and platelet recovery in transplant recipients who have received ex vivo-expanded products may be accelerated. The desired effects with regard to decreased incidence of infections, mortality rates, and long-term engraftment remain to be established and might be a function of the choice of cytokines and culture conditions.
The two cytokine combinations chosen in the study reported here gave similar levels of GM-CFC expansion after 6 days of culture, yet in neither case did the transplanted cells lead to more rapid WBC recovery. In fact, time to WBC recovery increased significantly with transplantation of CC 1-expanded cells and CC 2-expanded cells did not improve on recovery times compared with unmanipulated cells. No relationship was found between the degree of CFC expansion in culture and the time to platelet or neutrophil recovery. In the third experiment, where higher absolute numbers of Meg CFC were transplanted with either CC 1-or CC 2-expanded cells, no significant enhancement of platelet recovery was seen. Thus, the number of CFC of any class failed to predict changes in the initial speed of WBC or platelet recovery.
The results of our studies suggest that the cytokine combination chosen for ex vivo expansion will affect selected outcomes. In this study, cells cultured in CC 1 provided more rapid platelet recovery, but at the expense of WBC recovery and donor engraftment. Somewhat unexpectedly, CC 2, with GM-CSF and G-CSF, while giving levels of donor engraftment comparable to unmanipulated cells, did not enhance WBC recovery but compromised platelet recovery. These findings support the concept that hematological recovery during the immediate post-transplant period and subsequent donor engraftment are dissociated functions that can be influenced by exposure of BM cells to different cytokine combinations prior to transplantation.
These experiments utilized cytokines that are widely available and, in some cases, have been employed in the clinic. Are these the right cytokines for these experiments? Probably not. Others have reported very recently that different soluble cytokines, specifically Wnt proteins (61) (62) (63) and Bmi-1 (64, 65) , are capable of expanding the numbers of pluripotent murine stem cells in culture. However, it remains to be determined when and how these promising factors will be applied clinically.
